Author of

• 17842

  +

  P2.06 - Poster Session with Presenters Present (ID 467)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17889

    +

    P2.06-047 - LRRK2-In-1 Inhibit Proliferation of Doublecortin and CaM Kinase-Like-1 (DCLK1)-Positive Lung Cancer Cells (ID 4847)

    14:30 - 14:30  |  Author(s): Y. Mimura
    • Abstract
    • Slides

    Background:
    Doublecortin and CaM kinase-like-1 (DCLK1) is a kinase that regulates microtubule polymerization in migrating neurons. DCLK1 is also suggested to be a tumor stem cell marker in colon and pancreatic cancer. The expression status of DCLK1 and its role in lung cancer remain largely unknown. LRRK2-IN-1, a potent therapeutic agent for the treatment of Parkinson’s disease, has shown to inhibit DCLK1 kinase activity.
    
    Methods:
    DCLK1 expression status in human non-small cell lung cancer (NSCLC) cell lines was examined by quantitative real-time RT-PCR and western blotting. Cell proliferation assay was made after treatments with either si-DCLK1 or LRRK2-IN-1.
    
    Results:
    DCLK1 was expressed in most of the cell lines examined in various degrees. In DCLK1-expressing cell lines, si-DCLK1 treatment showed growth inhibition. LRRK2-IN-1 treatment also showed growth inhibition, in a dose-dependent manner.
    
    Conclusion:
    DCLK1 can be a target molecule for NSCLC treatment. LRRK2-IN-1 might be therapeutic for DCLK1-expressing lung cancer, through inhibition of its kinase activity.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.